Triple-negative breast cancer: molecular subtypes and targeted therapy

Current Opinion in Obstetrics & Gynecology
Kim M Hirshfield, Shridar Ganesan

Abstract

Triple-negative breast cancers (TNBCs), lacking estrogen receptor expression and human epidermal growth factor receptor 2 amplification, have no effective targeted therapy. Large-scale comprehensive genomic analyses have allowed stratification of TNBCs by molecular features. We will review the recent data regarding the classification of these poor prognosis cancers and the associated potential targeted treatment approaches. TNBCs are a heterogeneous set of cancers characterized by a diverse set of gene-expression patterns and underlying genomic changes. Mutations in p53 are the only genomic alteration present in the majority of TNBCs. Other potential targetable alterations are only present in small subsets of TNBCs, and include defects in DNA repair present in BRCA1-mutant TNBCs and some sporadic TNBCs. Antiandrogens may be effective for TNBCs that express the androgen receptor and have luminal-like gene-expression features. PI3KCA pathway inhibitors and HSP90 inhibitors may also be effective in a small fraction of TNBCs. Robust methods to functionally classify TNBCs to determine vulnerable pathways are urgently needed to guide the development of clinical trials. It is quite possible that TNBCs, like non-small cell lung cancer,...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Jul 29, 2004·Cancer Biology & Therapy·Ralph ScullyGanesh Nagaraju
May 3, 2006·Cancer Research·François BertucciDaniel Birnbaum
Aug 11, 2006·The New England Journal of Medicine·Cheng FanCharles M Perou
Sep 26, 2008·Breast Cancer Research and Treatment·Britta WeigeltJorge S Reis-Filho
Nov 26, 2009·Nature Reviews. Cancer·Christopher J BrownDavid P Lane
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz ByrskiSteven Narod
Dec 22, 2009·Breast Cancer Research and Treatment·Christine Y ShiangLajos Pusztai
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Aug 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monika GraeserNicholas C Turner
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Dec 8, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A VolleberghS C Linn
Mar 2, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D TryfonopoulosM J Duffy
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Oct 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard S FinnLori J Goldstein
May 12, 2012·Cancer Discovery·Nicolai J BirkbakAndrea L Richardson
May 26, 2012·Cancer Cell·Xin YuDarren R Carpizo
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa A CareyEric P Winer
Jun 23, 2012·Nature·Shantanu BanerjiMatthew Meyerson
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Jan 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H A AzimC Swanton
Apr 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ke-Da YuJenny C Chang
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaAhmad Awada
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko MasudaNaoto T Ueno
Aug 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ayca GucalpUNKNOWN Translational Breast Cancer Research Consortium (TBCRC 011)

❮ Previous
Next ❯

Citations

Feb 14, 2015·Current Oncology Reports·Brenda Ernst, Karen S Anderson
Jun 4, 2016·Breast Cancer Research and Treatment·Andrew J RoblesSusan L Mooberry
Dec 17, 2014·BMC Cancer·Maria D CaoTone F Bathen
Jul 28, 2016·Gynécologie, obstétrique & fertilité·H PorthaC Coutant
Nov 4, 2017·International Journal of Molecular Sciences·Nalo HamiltonRichard Pietras
Mar 2, 2019·Critical Reviews in Clinical Laboratory Sciences·Stella K Vasiliou, Eleftherios P Diamandis
Aug 26, 2014·Annals of Surgical Oncology·Jung Eun ChoiYoung Kyung Bae
Dec 19, 2013·Current Opinion in Obstetrics & Gynecology·Gottfried E Konecny
Mar 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Eva Y-H P Lee, Serena Abbondante
Dec 28, 2016·Journal of Cancer Research and Clinical Oncology·Xi ZhangSophie Doisneau-Sixou
Jun 4, 2017·Journal of Hematology & Oncology·Shang-Pen HuangYuan-Feng Lin
Oct 11, 2019·Journal of breast cancer·Maryam NakhjavaniAmanda R Townsend
Apr 15, 2015·The American Journal of Surgical Pathology·Lindsay WilliamsSimion I Chiosea

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.